Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 19/20 | 0.80 |
| ▸ | HSP90AB1 | P08238 | 19/20 | 0.80 |
| ▸ | HSP90B1 | P14625 | 5/20 | 0.80 |
| ▸ | TRAP1 | Q12931 | 4/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3625777 | 0.94 | HSP90AA1 (0.79) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL3625779 | 0.94 | HSP90AA1 (0.79) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL20878997 | 0.93 | HSP90AB1 (0.70) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL3625948 | 0.92 | HSP90AA1 (0.77) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL3632641 | 0.92 | HSP90AA1 (0.91) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL20878861 | 0.92 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL5004645 | 0.90 | HSP90AB1 (0.70) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL3631790 | 0.90 | HSP90AB1 (0.70) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL3632541 | 0.89 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL2683159 | 0.89 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146967-A2 | TETRAHYDROINDOLE AND TETRAHYDROINDAZOLE DERIVATIVES | Serenex, Inc. (US) | 2010-01-27 | — | — | EP | claimed |
| WO-2008130879-A2 | TETRAHYDROINDOLE AND TETRAHYDROINDAZOLE DERIVATIVES | SERENEX, INC. (US) | 2008-10-30 | — | — | WO | claimed |
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | SERENEX, INC. | 2008-10-30 | — | — | US | claimed |
| US-9956293-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170136085-A1 | TARGETED THERAPEUTICS | TVA (ABC), LLC | 2017-05-18 | — | — | US | disclosed |
| US-20170128580-A1 | TARGETED THERAPEUTICS | TARVEDA THERAPEUTICS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-9597343-B2 | Targeted therapeutics | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170056511-A1 | TARGETED THERAPEUTICS | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2017-03-02 | — | — | US | disclosed |
| US-20170056510-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170049899-A1 | TARGETED THERAPEUTICS | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2017-02-23 | — | — | US | disclosed |
| US-20170014519-A1 | TARGETED THERAPEUTICS | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2017-01-19 | — | — | US | disclosed |
| US-9533002-B2 | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-β | BERG LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160375142-A1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS, INC. | 2016-12-29 | — | — | US | disclosed |
| US-20160143884-A1 | USE OF TETRAHYDROINDAZOLYLBENZAMIDE AND TETRAHYDROINDOLYLBENZAMIDE DERIVATIVES FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-05-26 | — | — | US | disclosed |
| US-20150253330-A1 | PRE-SELECTION OF SUBJECTS FOR THERAPEUTIC TREATMENT WITH AN HSP90 INHIBITOR BASED ON HYPOXIC STATUS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-09-10 | — | — | US | disclosed |
| US-20140154266-A1 | METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA | BERG PHARMA LLC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140079636-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. | 2014-03-20 | — | — | US | disclosed |
| WO-2008130879-A2 | TETRAHYDROINDOLE AND TETRAHYDROINDAZOLE DERIVATIVES | SERENEX, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | SERENEX, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | SERENEX, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128580-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885HSP90B1 3/4885 |
| US-20160375142-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885HSP90B1 3/4885 |
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | HSF1, HSP90AB1, TPH1 | HSP90AA1 4/4885HSP90AB1 2/4885HSP90B1 13/4885 |
| US-20170136085-A1 | TARGETED THERAPEUTICS | HSP90B1, HSP90AB1, CDC37 | HSP90AA1 4/4885HSP90AB1 2/4885HSP90B1 1/4885 |
| US-20170049899-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885HSP90B1 3/4885 |
| US-20170014519-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885HSP90B1 3/4885 |
| US-20170056511-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885HSP90B1 3/4885 |
| US-20170056510-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885HSP90B1 3/4885 |
| US-20160143884-A1 | USE OF TETRAHYDROINDAZOLYLBENZAMIDE AND TETRAHYDROINDOLYLBENZAMIDE DERIVATIVES FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) | HSP90AB1, HSP90B1, HSP90AB2P | HSP90AA1 4/4885HSP90AB1 1/4885HSP90B1 2/4885 |
| US-20140154266-A1 | METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 6/4885 |
| US-20140079636-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885HSP90B1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.